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Introduction: Core cerebrospinal fluid (CSF) biomarkers – Aβ42, Tau, and phosphory-
lated Tau (pTau) – have been recently incorporated in the revised criteria for Alzheimer’s
disease (AD). However, their widespread clinical application lacks standardization. Pre-
analytical sample handling and storage play an important role in the reliable measurement
of these biomarkers across laboratories.
Aim: In this study, we aim to surpass the efforts from previous studies, by employing a
multicenter approach to assess the impact of less studied CSF pre-analytical confounders
in AD-biomarkers quantification.
Methods: Four different centers participated in this study and followed the same
established protocol. CSF samples were analyzed for three biomarkers (Aβ42, Tau, and
pTau) and tested for different spinning conditions [temperature: room temperature (RT)
vs. 4°C; speed: 500 vs. 2000 vs. 3000g], storage volume variations (25, 50, and 75%
of tube total volume), as well as freezing-thaw cycles (up to five cycles). The influence of
sample routine parameters, inter-center variability, and relative value of each biomarker
(reported as normal/abnormal) was analyzed.
Results: Centrifugation conditions did not influence biomarkers levels, except for
samples with a high CSF total protein content, where either non-centrifugation or
centrifugation at RT, compared to 4°C, led to higher Aβ42 levels. Reducing CSF
storage volume from 75 to 50% of total tube capacity decreased Aβ42 concen-
tration (within analytical CV of the assay), whereas no change in Tau or pTau was
observed. Moreover, the concentration of Tau and pTau appears to be stable up to five
freeze–thaw cycles, whereas Aβ42 levels decrease if CSF is freeze-thawed more than
three times.
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Conclusion: This systematic study reinforces the need for CSF centrifugation at 4°C prior
to storage and highlights the influence of storage conditions in Aβ42 levels. This study
contributes to the establishment of harmonized standard operating procedures that will
help reducing inter-lab variability of CSF-AD biomarkers evaluation.
Keywords: Alzheimer’s disease, cerebrospinal fluid, biomarkers, BIOMARKAPD, standardized operating
procedures, b-amyloid, tau protein, phosphorylated tau protein
Introduction
Cerebrospinal fluid (CSF) biomarkers, Aβ42, Tau protein, and
phosphorylated Tau (pTau), are frequently assessed for their
proven value as hallmarks of initial and coursing neuropatholog-
ical events in Alzheimer’s disease (AD) (1, 2). Studies over the
years have shown a 250–300% increase of CSF Tau and pTau and
a decrease of about 50% in CSF Aβ42 in AD patients compared
to normal aging (3). The high sensitivity and specificity of these
markers have been shown to be useful in discriminating AD from
other dementias, as well as to identifyADbefore onset of dementia
(the stage known as mild cognitive impairment – MCI), both in
single-center and large-scale multicenter studies (4–7). Therefore,
biomarkers have recently been incorporated in the new proposed
revised criteria for AD (8). The development and application of
revised diagnostic criteria, which include biomarkers, will sub-
stantially improve the diagnostic accuracy for AD toward other
forms of dementia and can help anticipate the rate of progression
and early disablement in AD (9, 10). Besides giving clues to
pathogenic mechanisms of the disease, biomarkers can also favor
therapeutics development by signaling desired effects of drugs
in phase I–II clinical trials, allowing inclusion of early cases to
longitudinal studies and even identifying sub-groups of patients
in order to tailor treatment (11, 12).
However, in recent years, international scientific evaluation
studies regarding neurochemical diagnosis of neurodegenerative
diseases have shown that the inter-laboratory precision of those
biomarkers measurements requires optimization (13). Cut-offs
differ greatly between studies, and the widespread clinical appli-
cation of revised criteria for early AD is hampered by lack of
standardization of biomarkers (2, 8). These variations in biomark-
ers performance can be the result of several pre-analytical and
analytical factors. Pre-analytical factors include lumbar puncture
(LP), CSF handling, and storage procedures, while analytical fac-
tors are more assay-related, for instance to differences among
centers in training of technicians, operating procedures, or batch-
to-batch variations of kits (14, 15). Analytical outcome can also be
influenced by biological variables intrinsic to study participants,
such as genetic variations or relation between CSF and brain
volume (16).
Several international standardization initiatives are already
ongoing. Themost extensive is the global Alzheimer’s Association
external quality control program for CSF measurements led by
K. Blennow (17, 18), involving more than 80 laboratories world-
wide. However, it is still purely descriptive and does not provide
any active interventions to tackle variations. Among interested
and connected centers for harmonization of AD biomarkers, there
have been attempts to reach a consensus concerning CSF collec-
tion, handling, and storage, and to create uniformized standard
operating procedures (USOPs) (19, 20). Reasonable amount of
evidence already exists regarding how CSF biomarkers levels are
influenced by certain pre-analytical conditions. For instance, it has
been well-established that polypropylene (PP) tubes and pipet tips
should be used for CSF collection, handling, and storage, since
lipophilic proteins like Aβ peptides bind in a non-specific manner
to non-PP tubes (21, 22). Several laboratories have also reported
on the stability of CSF proteins between collection and storage
(13, 23, 24), and it is a common consensus that they are stable for
at least 5 days at 4°C (20). Moreover, some studies have analyzed
the influence of freeze/thaw cycles on CSF-AD biomarkers and
most have found a decrease in Aβ42 concentration as a result of
freeze/thaw cycles, but different results were found in the number
of cycles that led to this decrease.
However, all of these studies were done in a single center and
employing a limited number of samples, generally no more than
10 samples per experimental condition. Also, most of them only
address the effect of pre-analytical conditions on CSF Aβ42 and
Tau levels or just in Aβ42, with only a few studies looking at the
effect on pTau levels (13, 25). Therefore, a standardized protocol
for handling CSF is still needed to allow for multicenter studies
and data comparisons in a near future (18).
In 2011, a new consortium was launched under the scope
of Joint Program for Neurodegenerative Diseases (JPND), the
BIOMARKAPD, expected to exceed all ongoing initiatives as it
involved a real European effort to solve standardization issues. The
main aim of the project is to develop evidence-based guidelines
for measurement and use of biomarkers in AD and Parkinson’s
disease (PD) in clinical practice, within 48 sites from 21 European
countries and also Canada. The present multicenter study is part
of this transnational project and its main aim is to assess CSF
pre-analytical confounding factors, which have been less studied
so far, that can possibly affect assay performance and biomark-
ers measurements across laboratories. We intend to test a large
number of samples, for all three biomarkers, the effect of different
spinning CSF conditions (temperature and speed) and of storing
different CSF volumes per total tube volume into aliquots.We will
also extend the study of the impact of the number of freeze–thaw
cycles (up to five cycles) to pTau. By this, we expect to contribute
to the development of new feasible, CSF handling USOPs that will
help reducing interlaboratory variability of CSF-AD biomarkers.
Materials and Methods
Participants
Four centers (Neurochemistry Laboratory, Coimbra University
Hospital, Portugal; Institute of ClinicalMedicine-Neurology, Kuo-
pio University Hospital, Finland; Danish Dementia Research
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TABLE 1 | Participating centers and their sample contribution for the
evaluation of CSF pre-analytical conditions (temperature and speed of
centrifugation, CSF%/tube volume, and number of freeze/thaw cycles) on
Aβ42, Tau, and pTau levels.
Centrifugation %CSF/tube
vol.
Freeze–thaw
cycles
Temperature Speed
Coimbra (Portugal) 27 22 30 27
Ctr= 0%; AD= 25.8%;
MCI= 12.1%
OD= 28.8%; OT= 33.3%
Copenhagen (Denmark) 8 8 – –
OT= 100%
Kuopio (Finland) 10 – 10 10
Ctr= 10%; AD= 2.5%;
MCI= 2.5%
OD= 5%; OT= 80%
Lyon (France) 10 10 10 3
Ctr= 4.5%; AD= 18.2%;
MCI= 4.5%
OD= 36.4%; OT= 13.6%
TOTAL= 136 55 40 50 40
Ctr, healthy controls; AD, Alzheimer’s disease; MCI, mild cognitive impairment; OD, other
dementias; OT, other.
Centre, Copenhagen University Hospital Rigshospitalet, Copen-
hagen, Denmark; Neurobiologie, University of Lyon, Lyon,
France) participated in this study. All laboratories handled CSF
samples in a standardized way, through the same previously estab-
lished protocol. Contributions in terms of number of samples
were variable (see Table 1). This study has been approved by the
Ethical board of Coimbra’s University Hospital, by local Ethical
committee of French Ministry of Research and Higher Educa-
tion, Ethical committee from the Capital Region of Denmark,
and by Research Ethics Committee Hospital District of Northern
Savo.
CSF Collection
The study was performed with freshly collected CSF samples,
obtained by LP in the L3/L4 or L4/L5 intervertebral space by
clinicians in the Neurology Departments of each center, using
a 20 or 25G needle and collected to 10mL standardized PP
tubes (Sarstedt 62.610.201). A total of 136 samples were collected
from patients with different diagnoses, five of them not classi-
fied (healthy controls – 3.7%; MCI – 7.4%; AD – 16.2%; other
dementia – 21.3%; other diagnosis – 47.8%). A small amount of
CSFwas used for routine analysis including cytological (white and
red cell count) and chemical analysis (total protein and glucose
content). From a total of 133 patients with this information,
50.7% had normal RBC count and 47.1% abnormal count; for
CSF total protein, 69.1% had normal (n= 88; 32.2 6.9mg/dL;
15–44mg/dL) content and 27.9% abnormal (n= 44; 61.2 14.3,
45–99mg/dL). The remainingCSFwas processed according to the
different pre-analytical conditions to be tested further on. In all
cases, samples were handled at room temperature (RT) (18–25°C),
and exposure to light and time betweenCSF collection and storage
did not exceed 2 h.
Tested Pre-Analytical Conditions
Centrifugation
For each sample, CSF was first aliquoted (380µL) into five PP
tubes of 500µL (Sarstedt ref. 72.730.006). Tube C1 was not
spinned at all and was left standing at RT without spinning until
other tubes were ready (kept into an intermediate tube until trans-
fer to final aliquot in order to keep the same procedure compared
to other centrifuged conditions); Tube C2 was centrifuged for
10min, 2000 g at RT; Tube C3 was centrifuged for 10min,
2000 g but at 4°C (standard condition used for routine process-
ing at all four centers); Tube C4 and C5 underwent spinning for
10min at RT, the former at 500 g and the latter at 3000 g.
Tubes C2 andC3were used to test the effect of temperature during
centrifugation and Tubes C2, C4, and C5 to test for speed.We also
compared Tubes C1 (no spinning) and C3 (routine protocol). The
supernatant of centrifuged CSF, as well as the non-centrifuged
CSF, was then immediately transferred from spinning tubes to
final set of tubes (500µL Sarstedt ref. 72.730.006) and frozen at
 80°C until analysis.
To test the impact of RBC count in CSF, five different samples
were spiked with blood at 1/1000 (3.6µL in 3.5mL of CSF) to
reach a final number of 5000 RBC/µL (10%). The spiked CSF
was aliquoted and treated as described above.
CSF%/Tube Volume
For each sample, CSF was first centrifuged for 10min, 2000 g
at 4°C, and then aliquoted into tubes, as described above, in
order to fill different percentages of total tube volume – V1 (25%;
i.e., 500µL in a 2mL tube; Sarstedt ref. 72.694.007); V2 (50%;
250µL in a 500µL tube; this volume represents the minimum
amount required to perform the assays for Aβ42, Tau, and pTau);
V3 (75%, our baseline condition, i.e., 380µL in a 500µL tube).
The aliquoted CSF was then immediately stored at  80°C until
analysis.
Freeze/Thaw Cycles
To test this condition, we aliquoted the same volume (380µL) of
centrifuged CSF (10min, 2000 g at 4°C) into three 500µL tubes
and stored them at  80°C. One of them (F1, baseline condition)
was left frozen until themoment of analysis; for tube F2, we forced
two freeze–thaw cycles (left on the benchtop for 2 h at RT to
mimick assay time on two consecutive days after collection) prior
to analysis, whichwould account for a total of three cycles; for tube
F3, four freeze/thaw cycles were done prior to the day of analysis,
therefore reaching a total of five freeze/thaw cycles.
CSF Analysis
All samples were quantified within 1month of storage at  80°C.
CSF levels of Aβ42, total Tau, and pTau 181P were deter-
mined using commercially available single-analyte ELISA kits
[INNOTEST® β-AMYLOID (1–42), INNOTEST® hTAU-Ag, and
INNOTEST® PHOSPHO-TAU (181P), Fujirebio, Spain], accord-
ing to the manufacturer’s instructions and consensus practices
from within BIOMARKAPD consortium. All samples were run
in duplicate and all conditions tested for the same sample were
run simultaneously on the same ELISA plate. Concentrationswere
extrapolated from a four-parameter Sigmoidal Curve. If the CV
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of duplicates was >20%, samples were excluded from the study
to avoid additional confounding factors. If concentrations were
below the limit of detection of the method, the value was set
equal to the lowest standard of the calibration curve. None of
the samples were above the concentration of the highest standard
for each of the assays. Results were expressed in picogram per
milliliter and as a relative percentage of the baseline conditions.
All the participants in the study were asked to classify each sample
as “normal” or “abnormal,” according to their own cut-off levels
for Aβ42, Tau, and pTau.
Statistical Analysis
The statistical analysis was accomplished with SPSS for Windows
version 22.0 and Graph Pad Prism 6.0. The following variables
were tested for each protein assay (Aβ42, Tau, and pTau): centrifu-
gation temperatures – “2000 g/4°C” vs. “2000 g/RT”; cen-
trifugation speeds – “RT/500” vs. “RT/2000” vs. “RT/3000 g,”
and also “no spinning” vs. protocol (2000 g/4°C); percentage
of CSF per total tube volume – “25” vs. “50” vs. “75%”; for
freeze/thaw cycles – “1” vs. “3 ” vs. “5 cycles”. t-test was used
for pairwise comparisons. Repeated measures were first per-
formed for multiple comparisons and also adding the following
co-variates: “Center,” “Clinical Group,” “Biomarker classification”
as normal or abnormal according to laboratory cut-offs, “CSF
Total Protein,” and “RBC count” either as scale or ordinal variable.
Post hoc tests (Bonferroni’s) were applied to repeated measures
testing, whenmultiple comparisons were significant. Correlations
between variables were performed using Pearson’s correlation
coefficient. As only five samples were used for studying the effect
of blood spiking in CSF, non-parametric tests for pairwise com-
parisons were used as Friedman and Wilcoxon.
Results
Influence of Centrifugation Parameters
We first analyzed the results obtained from non-centrifuged
aliquots comparing to those centrifuged under protocol condi-
tions (2000 g at 4°C for 10min). We observed no significant
difference between protein concentrations and found that the
absence of centrifugation seemed not to affect the outcome. Next,
we looked for variations within spinning temperatures, 4°C (rou-
tine protocol) and RT. No significant difference was observed for
any of the three biomarkers. When testing centrifugation speeds
(500, 2000, and 3000  g), still no statistically significant change
was seen in any of the biomarkers (Table 2).
Data were reanalyzed, testing the influence of the following
co-variates: “Center,” “Clinical Group,” “CSF Total Protein,” and
“RBC count” (both scale and dichotomized in normal/abnormal),
“Biomarker Classification” in normal or abnormal for each pro-
tein according to each laboratory cut-offs. “CSF Total pro-
tein (TP),” dichotomized as normal/abnormal, influenced the
effect of centrifugation conditions on Aβ42 levels (Figure 1A;
p= 0.029). Samples with high TP (>44mg/dL) had increased
levels of Aβ42 if centrifuged at RT (571.5 261.8) compared
to 4°C (549.4 238.0), whereas samples with normal TP had
higherAβ42 levels when centrifuged at 4°C (527.2 226.2, 4°C vs.
498.4 237.2, RT). Moreover, in samples with high TP content,
which were not centrifuged, Aβ42 levels tended to increase in
TABLE 2 | Concentration of each biomarker (picogram/milliliter) according
to the three different pre-analytical confounders.
Confounders Biomarkers (pg/mL)
Aβ42 Tau Phospho-Tau
Centrifugation
Non-centrifuged 548.6233.9
(n= 55)
315.2194.8
(n= 55)
47.025.0
(n= 55)
4°C 537.9224.7
(n= 55)
321.4197.4
(n= 55)
46.825.1
(n= 55)
RT 524.3241.0
(n= 55)
316.1191.0
(n= 55)
47.325.6
(n= 55)
500g 556.3230.1
(n= 40)
330.4211.6
(n= 40)
49.427.9
(n= 40)
2000g 558.6239.7
(n= 40)
330.6209.0
(n= 40)
49.027.6
(n= 40)
3000g 554.7234.0
(n= 40)
335.1216.2
(n= 40)
48.326.4
(n= 40)
% CSF/tube vol.
25 651.9337.1
(n= 50)
320.0214.9
(n= 50)
48.026.9
(n= 50)
50 636.7352.0
(n= 50)*
323.4232. 3
(n= 50)
47.625.8
(n= 50)
75 657.6334.4
(n= 50)
323.8230.1
(n= 50)
48.126.1
(n= 50)
Freeze–thaw cycles
1 time 597.9237.0
(n= 40)
353.9243.4
(n= 40)
47.530.1
(n= 40)
3 times 597.5243.2
(n= 40)
358.2245.2
(n= 40)
47.530.3
(n= 40)
5 times 569.8220.4
(n=40)‡,
358.5247.1
(n= 40)
47.830.5
(n= 40)
Results are expressed in meanSD (95% CI).
RT, room temperature; tube vol., tube volume.
Aβ42%CSF/Tube vol: *p< 0.05 vs. 75%; Aβ42 Freeze/Thaw cycles: p=0.072 vs. three
times; ‡p< 0.05 vs. one time.
Centrifugation: N=55-Ctr=7.3%; AD=18.2; MCI=7.3%; OD=23.6%; OT=41.8%;
N=40-AD=15%; MCI=7.5%; OD=30%; OT=45%; %CSF/Tube Vol.: Ctr=2.0%;
AD=18%; MCI=10%; OD=26%; OT=36%; freeze–thaw cycles: AD=25%;
MCI=10%; OD=20%; OT=45%.
relation to centrifugation under baseline conditions (Figure 1B;
p= 0.176). Other covariates had no impact concerning centrifu-
gation conditions for the three markers.
Regarding experiments with blood spiked CSF, as we have
tested only a limited number of samples, results are only indicative
and could be used to define a more precise protocol. We observed
no significant difference between protein concentrations using
variations in spinning temperatures, 4°C (routine protocol) and
RT. No significant difference was observed for any of the three
biomarkers. When testing centrifugation speeds (500, 2000, and
3000 g), again no statistically significant change was seen in any
of the biomarkers. However, when we compared data obtained
after centrifugation (routine protocol) and no centrifugation, we
found a statistical increase of mean levels of Aβ42 and pTau in no
centrifuged spiked samples by 6 and 11% (p< 0.05), whereas Tau
levels were not impacted by the absence of centrifugation (data
not shown).
Influence of CSF Percentage Per Total Tube
Volume
Wehypothesized that the amount ofCSF aliquoted in relationwith
total tube volume would have impact on protein concentration
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FIGURE 1 | (A) Significant influence of covariate “CSF Total protein content”
(dichotomized in normal/abnormal facing reference values) in the comparison
between Aβ42 levels after centrifugation at 4°C vs. room temperature
(p= 0.029) (TP, total protein; RT, room temperature). (B) Discrete influence of
covariate “CSF Total protein content” (dichotomized in normal/abnormal
facing reference values) in the comparison between Aβ42 levels after
centrifugation at 2000g/4°C vs. no spinning at all (p= 0.176). TP, total
protein; Absolute values – no spinning: normal TP – 529.7234.2, abnormal
TP – 579.2249.2); 4°C: normal TP – 498.4237.2, abnormal
TP – 549.4238.0.
mainly because of the adhesive ability of Aβ42 and possibly Tau
to tube walls, even though PP vials were always used throughout
the study. Thus, different CSF volume percentages were tested in
final aliquots and we found that decreasing the percentage of tube
filling from75% (baseline condition) to 50% resulted in a small but
significant reduction of 3.7% in Aβ42 concentration (p= 0.03).
This effect was indistinguishable from the analytical coefficient of
variation of the assay. Moreover, when further decreasing the per-
centage of tube filling to 25%, Aβ42 levels increased to levels simi-
lar to the ones observed under baseline conditions (Figure 2). Nei-
ther Tau nor pTau proteins levels were influenced by the amount
of CSF aliquoted in relation with total tube volume. Adding
covariates to our tests showed influence of “CSF Total protein”
(dichotomized as normal/abnormal) on pTau levels (p= 0.027),
particularly in 25% filling volume aliquots presenting abnormal
TP content (54.6 30.5) vs. normal TP (47.1 26.8) (Figure 3).
Other covariates had no impact in any of the three biomarkers.
Influence of Number of Freeze–Thaw Cycles
In this section, we tried to simulate the frequent real-life need
of defrosting a sample for other purposes, prior to biomarker
measurements. Therefore, we compared the results of a regu-
lar procedure, where the sample is just thawed for biomarker
FIGURE 2 | Observed differences in Aβ42 levels between aliquots with
25 vs. 50 vs. 75% of total tube volume (75 vs. 50%, p= 0.03). Results
expressed in relative percentage, facing the baseline condition (75% of tube
volume representing 100%). Absolute concentration levels (meanSD):
25% – 651.9337.1; 50% – 636.7351.9; 75% – 657.6334.4.
FIGURE 3 | Influence of covariate “CSF Total protein” (dichotomized in
normal/abnormal facing reference values) in the comparison between
pTau levels after aliquoting with different percentages of CSF per tube
volume – 25 vs. 50 vs. 75% (p= 0.027). TP, total protein.
assessment (one cycle), with other possible situations (thawed for
two and four times prior to protein assay).
We observed that while Tau and pTau remain stable for up
to the five freeze/thaw cycles, the same is not true for Aβ42.
Although thawing the CSF sample three times did not change the
measured Aβ42 levels, a statistical significant reduction of 5.0% in
Aβ42 levels was observed when the number of freeze–thaw cycles
was increased to 5 (Figure 4; p= 0.028). However, this decrease
remained in the analytical coefficient of variation of the assay.
Covariate inclusion had no impact, concerning the effect of the
number of freeze/thaw cycles, for the three markers.
As the presence of increased total CSF proteins was the
only covariate influencing the results, we studied the correlation
between the levels of each biomarker and CSF protein content.We
found significant correlations (p< 0.05, data not shown) between
pTau levels and CSF TP in both non-centrifuged and centrifuged
samples under protocol conditions (2000 g, 4°C).
Discussion
There have been a few studies exploring potential CSF pre-
analytical confounders, but a systematic analysis of some
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FIGURE 4 | Observed differences in Aβ42 levels between samples
freeze/thawed three and five times prior to the moment of analysis
(1 cycle) (1 vs. 5 cycles, *p=0.028; 3 vs. 5 cycles, +p=0.072).
Absolute concentration levels (meanSD): one time – 597.9237.0; three
times – 597.5243.2; five times – 569.7220.4.
conditions, such as centrifugation, storage volumes, and
freeze/thawing cycles, is still missing. To the best of our
knowledge, our study has so far the largest number of samples
(over 40 samples for each condition) testing systematically
these three potential major sources of variability. This study
includes samples from different cohorts of patients with several
clinical diagnosis, validating our results for a broad range of
biomarkers quantitative values. Furthermore, the influence of
multiple co-variates was evaluated, and all other variables related
to CSF collection were strictly controlled (19, 26). In this study,
all LPs were performed in the morning, as although no clear
diurnal pattern in Aβ42 levels has been observed, a 1.5- to
4-fold variation in AD biomarkers during a 36 h period has been
reported (20). Moreover, fasting, as well as possible adsorption to
lumbar catheter walls during LP, was also suspected to influence
Aβ42 levels, but so far such effects could not be demonstrated
(27). Current guidelines regarding collection and storage tubes
(14) were also strictly followed and CSF was processed and
frozen within a maximum of 2 h after collection. According to
some reports, Aβ42 content is altered if CSF is not immediately
frozen (to avoid protein oxidation), while Tau proteins are
stable and can be kept at room temperature up to 24 h (25) or
even 4 days (13). The use of different types of tube materials
(polycarbonate, polystyrene, PP, and other copolymers) has
also been tested. In several studies comparing PP against others
plastics, authors never tested the variability among the different
PP tubes, therefore remaining a potential confounder (22, 27).
A few studies compared several PP tubes and concluded that
PP is not a warranty against adsorption and only specific tubes
reported to avoid adsorption could be recommended (21, 28, 29).
A very recent study has shown that even using only PP tubes,
Aβ42 levels are reduced up to 25% simply through multiple tube
transferences which, therefore, should be minimized (28).
Speed and temperature of CSF centrifugation vary considerably
between laboratories. Therefore, in this study, we tested both the
influence of spinning temperature (RT and 4°C) and speed (500,
2000, and 3000 g) on biomarkers levels. Overall, neither of these
conditions were found to influence the concentration of any of
the biomarkers. A previous study has looked for the influence of
CSF centrifugation protocols on Aβ42 levels (27) and observed a
significant decrease in Aβ42 concentration in centrifuged sam-
ples (10min, 2000 g, either at RT or 4°C) compared to non-
centrifuged samples. It has also been found that no difference
occurred in Aβ42 and Tau levels in CSF samples stored at 4°C
and centrifuged after 1, 4, 48, or 72 h (30). Furthermore, no dif-
ferences were found comparing centrifuged samples immediately
frozen and those left for 4 days at 4°C without spinning (30).
Centrifugation speed has been reported not to have an effect on
biomarkers levels, but the centrifugation of hemorrhagic samples
at 2000 g, RT, within 2 h after collection, in order to avoid cell
lysis, is recommended (26).
The inclusion of covariates in our analysis showed that, in
samples with a high total protein content, an increase in Aβ42
concentration upon centrifugation at RT occurs. It can be hypoth-
esized that Aβ42 can bind to excess protein, thus preventing the
adhesion to tube walls, and this interaction may be disrupted by
freeze/thawing. In contrast, in samples with normal or low TP
content, centrifugation at RT may promote the adhesion of Aβ42
to tube walls, leading to lower measured levels of the peptide.
As the largest discrepancy in Aβ42 levels between samples with
normal/abnormal TP is seen when centrifugation is done at RT,
spinning at 4°C should be applied routinely. In line with a previous
study, we also observed that no spinning increases the measured
levels of Aβ42 in samples with a high CSF total protein content
(27). We cannot neglect another hypothesis, consistent with a
competition between proteins present in high amounts to adsorb
onto the walls of tubes decreasing, therefore, the possibility of less
concentrated proteins, as amyloids, to stick to the plastic. This
characteristic is commonly used in ELISA test by saturating the
plastic wells with albumin, gelatin, or milk proteins after coating
the capture antibody. Currently, when 1 h at 37°C is enough to
saturate non-specific residual sites, it takes overnight at 4°C, what
is absolutely consistent with the recommendation we did, to spin
at low temperature.
Despite the generalized use of atraumatic needles, the influence
of blood contamination is still relevant, and controversial results
have been reported. Bjerke et al. observed that up to 5000 RBC/µL
of CSF had no effect on Aβ42 levels (27). However, Zimmermann
et al. showed that approximately 1 g/L of CSF protein levels (that
can happen after traumatic tap or in patients with disrupted blood
brain barrier) could have an impact on AD biomarkers (13). In
our study, the inclusion of RBC count as a co-variate had no effect
on biomarkers levels. However, the majority of our samples had
low or just above threshold RBC counts, thus the influence of CSF
contamination with RBC could not be ruled out. Spiking blood in
CSF was tested for few samples, the final concentration of RBC
being 5000/µL of CSF. Even if, they need to be confirmed, as
the increase of levels was found under or close to the analytical
CV of duplicates of 10%, our preliminary data are consistent
with current guidelines in which it is recommended to centrifuge
samples to avoid blood contamination. Further studies should be
madewith spiked CSF to clarify the influence of high RBC content
on biomarkers quantification, using at least different amounts of
spike, for example, in a range of RBC 5000–10,000/µL.
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Aliquot storage volume is another potential pre-analytical con-
founder that has not been often assessed. We addressed this
potential source of variation by storing three different ratios (25,
50, and 75%) of CSF volume per total tube capacity. The tube
filling volume did not influence CSF levels of Tau and pTau. Con-
cerning Aβ42 levels, they decreased when CSF storage volume
decreased from 75 to 50% and amazingly, they slightly increased
in 25% filled tubes, as compared to 50% filling. The variations
were found lower than the accepted analytical intra-assay range-
to-average of duplicates (<20%), so in our study using aliquots
in tubes of 500µL, the filling tube is not a strong confounder. It
can be hypothesized that decreasing the ratio of CSF volume to
surface area of storage tube would lead to an increased analyte
adsorption to the internal walls of the tube, lowering its levels in
solution. Our results are in accordance with a recent study testing
the influence of a wide range of CSF volumes (2.5–75% of CSF
per total tube volume) in Aβ42, Tau, and pTau measurements
(31). While Tau and pTau remained stable with the increase in
storage volume percentage, they found that a volume increase of
10µL caused an Aβ42 increase of 1 pg/mL, which is absolutely
consistent with the increase of 3.7% between 250 and 380µL
(13 pg/mL) that we have found. In the studies by Toombs and
colleagues (28, 31), the addition of 0.05% Tween 20 to the aliquots
resulted in considerably higher concentrations of Aβ42, suggest-
ing that in the presence of detergent a higher proportion of Aβ42
molecules were free in solution, thus supporting the hypothesis
of protein adsorption to the tube walls, as previously reported
(27). This is consistent with the fact that Tween 20 is used as a
blocking agent in ELISA plates, avoiding further adsorption of
proteins.
The influence of freeze/thaw cycles (one, three, and five) during
CSF storage, before protein measurements, was also investigated.
We observed that Tau and pTau levels were not altered, but
Aβ42 levels decreased slightly (5%) with repeated freeze/thawing,
especially above three cycles, but as reported for filling tube
study, this decrease was under the accepted analytical intra-
assay range-to-average of duplicates (<20%); so, in our study,
using three freeze/thaw cycles has no strong effect onto the
CSF levels of biomarkers. Our data are consistent with those of
Zimmerman et al. (13) reporting the stability for up to three
freeze/thaw cycles for the three biomarkers and partially with
those of Simonsen et al. (24) reporting stable levels for Aβ42
but increased levels for pTau without inhibitors of protease.
Our data are mainly different with those obtained in the study
of Schoonenboom et al. (30), in which they showed that after
three freeze–thaw cycles (for 2 h) Aβ42 levels decreased by 20%,
mainly after the first cycle whereas Tau protein was not altered
by six freeze–thaw cycles. In this last study, the exact reference
of PP tubes used for the study was not done, whereas in study
of Simonsen et al., the tubes were exactly the same that those
we selected as tubes known to present a minimal adsorption
of amyloid. So, the difference between data concluding absence
of strong effect onto amyloid levels and those showing large
decrease of amyloid levels could be explained by a larger syner-
gistic effect of adsorption and freeze/thaw process in studies in
which the reference of tubes was not given and the adsorption
of amyloid onto tubes was not checked (30). Therefore, most of
TABLE 3 | Recommendations for CSF pre-analytical handling prior to
evaluation of AD biomarkers.
Confounder Recommendation
Spinning Right after collection (within 2 h max); at 2000g
4°C – avoid multiple tube transfers
Storage volume Tubes should be filled up close to total tube capacity to
keep constant the relation surface area/tube walls
Freeze–thaw cycles Avoid more than three cycles to prevent protein degradation
the data obtained before the standardization of tubes must be
interpreted with caution.
It should also be emphasized that, in our study, all measure-
ments were carried out within 1month storage and it cannot
be ruled out that in samples kept for longer storage periods,
different results could be obtained. We wanted to know to what
extent the analysis of each condition would change after 1 and
2 years of storage. This was not performed after all, since it would
surpass the length of the project. However, we would be reason-
ably comfortable to perform this analysis since there have been a
few studies addressing the long-term stability of CSF biomarkers,
concluding that Aβ42 and Tau proteins remain stable up to 6 years
(if stored at  80°C immediately after collection and processing)
(23), supporting the feasibility of biobanking over a large period
of time. Thus, having this factor controlled, it would be possible
to test variations within pre-analytical conditions.
In recent years, a strong effort has been done to develop and
implement USOPs for CSF analysis, and this is also a major
goal of the JPND-BIOMARKAPD Consortium. However, overall
variability remains too high to allow assignment of universal
biomarker cut-off values and is still compromising AD-like scores
across laboratories (32–34). Taking this into account, our findings
reinforce the existing guidelines and support new recommenda-
tions for CSF pre-analytical SOPs (Table 3).
We propose that centrifugation should be performed as fast
as possible after CSF collection, at 4°C, the speed conditions
being not a major factor (500, 2000, or 3000 g); multiple tube
transfer of CSF should be avoided and kept to aminimum. Storage
aliquots should be filled up close to the maximum tube capacity
in order to keep a constant surface area and avoid sublimation. It
is preferable that samples should not be submitted to more than
three freeze–thaw cycles to prevent protein degradation.
We strongly believe that this work will contribute to the estab-
lishment of core and broadly used feasible guidelines that will
enable decisive AD large scale studies.
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